Eli Lilly's Combination Drug Trial Shows Greater Weight Loss but Higher Discontinuation Rates
Eli Lilly recently released trial results showing that a combination treatment of tirzepatide (Zepbound) with eloralintide led to greater weight loss compared to using either drug alone. Patients taking the combo lost up to 23.3% of their body weight, significantly higher than those on tirzepatide alone who saw about 14.8%. However, a notable drawback was that nearly 27% of participants discontinued treatment due to side effects. Despite this challenge, Eli Lilly's leadership in the GLP-1 obesity drug market remains strong and shows continued innovation aimed at maintaining its competitive edge. The company is actively seeking better solutions for patients who may not tolerate existing treatments well or achieve desired results with them alone. While high discontinuation rates are a concern, they were previously observed during earlier trials of tirzepatide. Eli Lilly's stock currently trades near 40 times its trailing earnings and has a market cap exceeding $1 trillion. Although the valuation is steep, analysts believe there remains potential for growth due to the company’s dominant position in the anti-obesity drug space.
Tickers: $LLY